country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-143641

Copy Link Print Information

Anticancer agent 25

Anticancer agent 25 is an anticancer agent. Anticancer agent 25 can arrest the cell cycle at the G1 phase, and significantly inhibit tumor cell colony forming and migration even at low concentrations. Anticancer agent 25 can significantly induce cytoplasmic vacuolation. Anticancer agent 25 can be used for the study of prostate cancer, breast cancer, and colon cancer.

For research use only. We do not sell to patients.

CAS No.: 2401013-08-7
Formula: C₃₇H₄₅BrN₂O₃
Molecular Weight:645.67

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (272 KB)

Anticancer agent 25 Chemical Structure

CAS No.: 2401013-08-7

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

Cell Cycle/DNA Damage

0.19 μM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
DU-145	IC₅₀	0.74 μM Compound: 18e	Antiproliferative activity against human DU145 cells assessed as cell growth inhibition by SRB assay Antiproliferative activity against human DU145 cells assessed as cell growth inhibition by SRB assay	[PMID: 31812467]
HCT-116	IC₅₀	0.55 μM Compound: 18e	Antiproliferative activity against human HCT116 cells assessed as cell growth inhibition by SRB assay Antiproliferative activity against human HCT116 cells assessed as cell growth inhibition by SRB assay	[PMID: 31812467]
HT-29	IC₅₀	0.56 μM Compound: 18e	Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition by SRB assay Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition by SRB assay	[PMID: 31812467]
MDA-MB-231	IC₅₀	1.31 μM Compound: 18e	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition by SRB assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition by SRB assay	[PMID: 31812467]
PC-3	IC₅₀	0.19 μM Compound: 18e	Antiproliferative activity against human PC3 cells assessed as cell growth inhibition by SRB assay Antiproliferative activity against human PC3 cells assessed as cell growth inhibition by SRB assay	[PMID: 31812467]

In Vitro

Anticancer agent 25 (Compound 18e) shows antiproliferative activity against prostate cancer cell lines, PC3 (IC₅₀ = 0.19 μM) and DU145 (IC₅₀ = 0.74 μM); breast cancer cell line MDA-MB-231 (IC₅₀ = 1.31 μM); and human colon cancer cell lines, HT29 (IC₅₀ = 0.56 μM) and HCT116 (IC₅₀ = 0.55 μM); and exhibits low toxicity against normal human aortic fibroblasts (HAF) (IC₅₀ = 3.95 μM)^[1].
Anticancer agent 25 (0.5-2 μM, 24 h) induces G1 phase arrest in PC3 cells in a dose-dependent manner^[1].
Anticancer agent 25 (0.1-2 μM, 24 h) can significantly inhibit the long-term proliferation ability of PC3 tumor cells even at extremely low concentrations^[1].
Anticancer agent 25 (0.1-2 μM, 24 h) significantly and in a dose-dependent manner inhibits the migration ability of PC3 cells^[1].
Anticancer agent 25 (0.5-1 μM, 24 h) can induce significant cytoplasmic vacuolation in PC3 cells even at low concentrations^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis^[1]

Cell Line:

PC3 cells
Concentration:

0.5 μM, 1 μM, 2 μM
Incubation Time:

24 h
Result:

Caused ~ 50% inhibition on the colony forming at 0.1 μM and ~ 90% inhibition at 0.5 μM.

Chemical Information

CAS No. 2401013-08-7
Molecular Weight 645.67
Formula C₃₇H₄₅BrN₂O₃
SMILES

CC(C)C(C=C1)=CC=C1CC2=C3C=CC(OC)=C(NCCCCCCCC)C3=C[N+]4=C2C5=CC6=C(C=C5CC4)OCO6.[Br-]
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (272 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Wang ZC, et al. Synthesis and anticancer activity of novel 9,13-disubstituted berberine derivatives. Bioorg Med Chem Lett. 2020 Jan 15;30(2):126821. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote